Structured analysis is blocked pending operator review
Last SEC check
Sep 14, 2026
Filing → research
17 min
Data basis
Official SEC · no quote feed
Component status
Filing EvidenceResearch CurrentOfficial SEC filing history is available
Structured FinancialsAnalysis BlockedThe latest filing model has no reviewed comparable financial mapping · METRIC_DURATION_CONTEXT_CONFLICT
Filing AnalysisAnalysis BlockedNo filing analysis job is currently running · METRIC_DURATION_CONTEXT_CONFLICT
Fundamental StateAnalysis BlockedFundamental State depends on validated comparable financial metrics · METRIC_DURATION_CONTEXT_CONFLICT
RESEARCH SNAPSHOTPhio Pharmaceuticals Corp.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
INSIDER STATE / 90DRecent disclosed activity
Open-market purchases
1
Sales
0
Distinct buyers
1
Repeat buyer
NO
Conservative Form 4 classification · not a sentiment label
Flagship analysis / V3
What changed?
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Current 10-Q0001437749-26-02627110 governed changes · top 7 shown
01
MEDIUM IMPORTANCEFree Cash Flow Proxy75TH HISTORICAL PCTL · N=4
Free-cash-flow proxy decreased 58.7%
Free-cash-flow proxy changed -58.7% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.